Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors – an autopsy study - Case Reports - Oncology · Hematology

RECOMMENDED

Skin Cancer

Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic Melanoma

J Immunother.

Dimitriou F, Matter AV, Mangana J, Urosevic-Maiwald M, Micaletto S, Braun RP, French LE, Dummer R

doi: 10.1097/CJI.

Skin Cancer

Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma

Clin Kidney J.

Murakami N, Borges TJ, Yamashita M, Riella LV

doi: 10.1093/ckj/sfw024.

Further Publications

Management of Cutaneous Immune-Related Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Review

JAMA Oncol

Nadelmann ER, Yeh JE, Chen ST

doi: 10.1001/jamaoncol.2021.4318

Gastrointestinal CancerSkin Cancer

Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management

Cancer Treat Rev.

Sznol M, Postow MA, Davies MJ, Pavlick AC, Plimack ER, Shaheen M, Veloski C, Robert C

doi: 10.1016/j.ctrv.2017.06.002.

Lung, Respiratory and Thoracic Cancer

Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a metaanalysis

Oncotarget.

Kim JH, Kim HS, Kim BJ

doi: 10.18632/oncotarget.18703.

Lung, Respiratory and Thoracic Cancer

Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis

JAMA Oncol.

Blumenthal GM, Zhang L, Zhang H, Kazandjian D, Khozin S, Tang S, Goldberg K, Sridhara R, Keegan P, Pazdur R

doi: 10.1001/

Skin Cancer

Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma

Melanoma Res.

Yip RHL, Lee LH, Schaeffer DF, Horst BA, Yang HM

doi: 10.1097/CMR.

Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer: Results From the C SCANS Study

JAMA Oncol.

Cespedes Feliciano EM, Kroenke CH, Meyerhardt JA, Prado CM, Bradshaw PT, Kwan ML, Xiao J, Alexeeff S, Corley D, Weltzien E, Castillo AL, Caan BJ

doi: 10.1001/

Genitourinary Cancer

Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer

Prostate.

Markowski MC, Shenderov E, Eisenberger MA, Kachhap S, Pardoll DM, Denmeade SR, Antonarakis ES

doi: 10.1002/pros.23955.

Related content

Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic Melanoma

Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma

Management of Cutaneous Immune-Related Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Review

Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management

Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a metaanalysis

Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis

Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma

Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer: Results From the C SCANS Study

Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer